SPECIALIZED IN ANTIVIRAL SOLUTIONS

Dengue

The NTVIRIN have accomplished to cure the Dengue Fever and the efficacy have shown EIGHTY-FIVE PERCENT on in-vitro experiments. The formulated NTVIRIN has tested against Dengue-2 viruses and it performed better activities when it compared with Ribavirin, as a standard.
The efficacy of the NTVIRIN has evaluated by MTT assay method. A series of NTVIRIN solution concentrations in terms of µM/ml have treated against the Dengue-2 virus strains.

The Anti-Viral activities of the NTVIRIN Solutions increased on the course of 72 hours on viral strains and it has been found to be 85% antiviral activities. |The IC50 of NTVIRIN has also been found to be at 19.99 µM/ml. Most people with dengue have mild or no symptoms and will get better in 1–2 weeks. Rarely, dengue can be severe and lead to death. If symptoms occur, they usually begin 4–10 days after infection and last for 2–7 days.

Symptoms may include:

HIGH FEVER (40°C/104°F), SEVERE HEADACHE, PAIN BEHIND THE EYES MUSCLE AND JOINT PAINS, NAUSEA, VOMITING, SWOLLEN GLANDS, RASH. SEVERE DENGUE SYMPTOMS OFTEN COME AFTER THE FEVER HAS GONE AWAY EVERE ABDOMINAL PAIN, PERSISTENT VOMITING, RAPID BREATHING, BLEEDING GUMS OR NOSE,FATIGUE, RESTLESSNESS BLOOD IN VOMIT OR STOOL, BEING VERY THIRSTY, PALE AND COLD SKIN, FEELING WEAK.

TRANSMISSION CYCLE

The transmission system of the dengue virus begins when the mosquito bites an infected person; the virus multiplies in the gut of the insect and passes into other organs, finally reaching the salivary glands, from where it must exit through the bite into the bloodstream of another person not yet infected.

The risk of contracting dengue infection has increased dramatically since the 1940s. This upward trend is due to increases in long-distance travel, population growth and urbanization, lack of sanitation, ineffective mosquito control, and increases in the surveillance and official reporting of dengue cases. Dengue has spread through SOUTHEAST ASIA, THE PACIFIC ISLAND COUNTRIES, AND THE MIDDLE EAST. Today, approximately 40% of people live in regions of the world where there is a risk of contracting dengue.

Dengue is an endemic disease, which means that it occurs regularly, in tropical regions of the world. The disease is endemic in more than one hundred countries in Africa, the Americas, Asia, the Caribbean, and the Pacific

MARKET STRATEGY OF DENGUE-2 PHARMACEUTICALS

Dengue Fever is caused by the dengue virus (DENV), transmitted to humans through the bite of infected female mosquitoes, Aedesaegypti mosquitos. Over the last 50 years, there has been 30-fold increase in the reported number of dengue cases globally. Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.
The incidence of dengue has grown dramatically around the world in recent decades, with cases reported to WHO increased from FIVE HUNDRED THOUSAND CASES in 2000 to FIVE MILLION IN 2019. Global Dengue Fever Treatment Market is expected to garner a market value of US$ 455.65 MILLION IN 2023 AND IS EXPECTED TO ACCUMULATE A MARKET VALUE OF US$ 1.34 BILLION BY REGISTERING A CAGR OF 11.84 % IN THE FORECAST PERIOD 2023 TO 2033. The market for Dengue Fever Treatment registered a CAGR of 11% in the historical period 2018 to 2022. One modelling estimate indicates 390 million dengue virus infections per year of which 96 million manifest clinical and 3.9 billion people are at risk of infection with dengue viruses.
During latest by 2022- 2023 years, high number of cases were reported in Brazil (2,182,229), and perhaps Bangladesh (101 000), Malaysia (131 000) Philippines (201,509), Vietnam (325 604) India (110,473) Indonesia. (94,355) in Asia

NTVIRIN ANTI-DENGUE PHARMACEUTICALS

There is no specific treatment for dengue/severe dengue, and early detection and access to proper medical care greatly lower fatality rates of severe dengue. However, in severe cases Fluid replacement and platelet increasing are practiced.

However, several therapeutic options have been proposed, and some are being used to reduce infection outcomes. Several sulfated polysaccharides and antipyretics are in use against dengue because of their observed and approved antiviral properties.

Moreover, the medicines practiced at normal middle class hospitals are, pain killers, higher ranked broad spectrum antibiotic have some serious side effects till life period of patients.

” NTVIRIN SOLUTIONS HAVE FOUND TO BE UNIQUE MEDICINE
AGAINST A1L KIND OF DENGUE VIRAL INFECTION “